familial Alzheimer's Disease
GPTKB entity
Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:psychologist
|
| gptkbp:advocates_for |
increased awareness
critical for research funding |
| gptkbp:associated_with |
amyloid plaques
tau tangles neurodegeneration early onset dementia |
| gptkbp:caused_by |
genetic mutations
|
| gptkbp:clinical_trial |
ongoing research
|
| gptkbp:collaborations |
between researchers and clinicians
|
| gptkbp:community_impact |
affects families worldwide
|
| gptkbp:first_described_by |
in the 1990s
|
| gptkbp:future_plans |
focuses on prevention strategies
aims to find cures explores new therapies |
| gptkbp:genetic_diversity |
recommended for families
APP gene PSE N1 gene PSE N2 gene |
| https://www.w3.org/2000/01/rdf-schema#label |
familial Alzheimer's Disease
|
| gptkbp:impact |
patients and families
|
| gptkbp:is_a_resource_for |
available for support
available for understanding the disease |
| gptkbp:is_involved_in |
available for families
|
| gptkbp:is_popular_in |
rare compared to sporadic Alzheimer's
|
| gptkbp:number_of_teams |
varies among individuals
|
| gptkbp:provides_information_on |
developed for management
|
| gptkbp:public_awareness |
important for early detection
|
| gptkbp:receives_funding_from |
increasing in recent years
|
| gptkbp:research_focus |
biomarkers
genetic factors |
| gptkbp:risk_factor |
age
lifestyle factors family history |
| gptkbp:screenings |
recommended for at-risk individuals
|
| gptkbp:social_responsibility |
genetic testing
clinical assessment NINCDS-ADRDA criteria |
| gptkbp:supports |
often required
|
| gptkbp:symptoms |
cognitive decline
nutritional support physical activities memory loss behavioral changes cognitive therapies |
| gptkbp:transmission |
autosomal dominant inheritance
|
| gptkbp:treatment |
medications
supportive care |
| gptkbp:type_of_care |
financial strain
emotional burden significant stress |
| gptkbp:bfsParent |
gptkb:Sporadic_Alzheimer's_Disease
|
| gptkbp:bfsLayer |
8
|